Clinical Trials Logo

Liposomal Bupivacaine clinical trials

View clinical trials related to Liposomal Bupivacaine.

Filter by:
  • None
  • Page 1

NCT ID: NCT06430112 Recruiting - Clinical trials for Postoperative Analgesia

Liposomal Bupivacaine vs Ropivacaine for TAPBs

Start date: November 1, 2023
Phase: Phase 3
Study type: Interventional

Few studies have compared the efficacy of ultrasound (US)-guided TAP blocks with Liposomal bupivacaine(LB) versus ropivacaine in reducing postoperative opioid usage in patients undergoing laparoscopic lower abdominal tumor Resection. Therefore, we are conducting this prospective, randomized controlled trial to compare the postoperative analgesic effects of LB and ropivacaine for TAP blocks among patients undergoing laparoscopic colorectal procedures.

NCT ID: NCT06145165 Recruiting - Clinical trials for Postoperative Recovery

A Analgesic Study of Adductor Canal &IPACK Block With Liposomal Bupivacaine in Knee Arthroplasty

Start date: December 1, 2023
Phase: Phase 1
Study type: Interventional

To study the effectiveness of ACB and iPACK block with liposomal bupivacaine for postoperative analgesia in patients undergoing knee arthroplasty

NCT ID: NCT04751344 Recruiting - Postoperative Pain Clinical Trials

Liposomal Bupivacaine Versus Bupivacaine Plain for Operative Pain Management of Forefoot Surgery

Start date: June 16, 2020
Phase: Phase 4
Study type: Interventional

Prospective, randomized, controlled single-blinded trial comparing liposomal bupivacaine with bupivacaine HCl for postoperative management. Upon completion of the forefoot procedure in the operative room the subject will be entered into the randomization system which will specify whether to inject 10cc (5mg/mL) of bupivacaine HCl or 8cc (13.3 mg/mL) liposomal bupivacaine, both considered routine care procedure. Thereafter, postoperative pain will be assessed and measured using a Visual Analog Scale (VAS) scoring scale post-operatively at 2 hours, 24 hours, 48 hours and 72 hours. In addition, the amount of oral morphine equivalents (OME) required postoperatively and time to first use of OME will be measured. Our hypothesis is that patients who received liposomal bupivacaine will have less post-operative pain and require less OMEs.